MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.95
-1.35
-4.77%
After Hours: 26.95 0 0.00% 16:06 05/18 EDT
OPEN
27.71
PREV CLOSE
28.30
HIGH
27.99
LOW
26.88
VOLUME
800.04K
TURNOVER
6.34M
52 WEEK HIGH
34.50
52 WEEK LOW
23.15
MARKET CAP
1.44B
P/E (TTM)
20.85
1D
5D
1M
3M
1Y
5Y
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 3d ago
Supernus Pharmaceuticals Q1 EPS $0.43 Up From $0.11 YoY, Sales $152.50M Up From $130.93M YoY
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.43 per share. This is a 290.91 percent increase over earnings of $0.11 per share from the same period last year. The company reported $152.50
Benzinga · 05/09 20:34
Supernus Pharmaceuticals GAAP EPS of $0.43 misses by $0.02, revenue of $152.51M beats by $2.04M
Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q1 GAAP EPS of $0.43 misses by $0.02. Revenue of $152.51M (+16.5% Y/Y) beats by $2.04M. Non-GAAP operating income of $28.0 million. U.S. Food and
Seekingalpha · 05/09 20:15
Supernus Pharmaceuticals Reports Higher Q1 Earnings, Revenue; Affirms 2022 Revenue Guidance
MT Newswires · 05/09 16:55
-- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 EPS $0.43, vs. Street Est of $0.45
MT Newswires · 05/09 16:40
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
Supernus Pharmaceuticals Q1 2022 Earnings Preview
Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is $0.45 (+225.0% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/06 21:35
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that ...
GlobeNewswire · 05/02 20:55
More
No Data
Learn about the latest financial forecast of SUPN. Analyze the recent business situations of Supernus Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SUPN stock price target is 35.50 with a high estimate of 44.00 and a low estimate of 30.00.
High44.00
Average35.50
Low30.00
Current 26.95
EPS
Actual
Estimate
0.110.210.320.43
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 395
Institutional Holdings: 65.78M
% Owned: 123.16%
Shares Outstanding: 53.41M
TypeInstitutionsShares
Increased
88
1.94M
New
42
1.92M
Decreased
67
2.18M
Sold Out
28
920.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.81%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Non-Executive Chairman/Independent Director
Charles Newhall
President/Chief Executive Officer/Secretary/Director
Jack Khattar
Chief Financial Officer/Senior Vice President
Timothy Dec
Senior Vice President/Chief Scientific Officer
Padmanabh Bhatt
Senior Vice President
Tami Martin
Senior Vice President
Frank Mottola
Senior Vice President
Jonathan Rubin
Independent Director
Carrolee Barlow
Independent Director
Frederick Hudson
No Data
No Data
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.